Search Results
Aug 27, 2026, 10:04 ET Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
Antibody): HBM9013/HAT001 is a potent and selective anti-CRH neutralizing antibody for various disorders including congenital adrenal hyperplasia (CAH). In February 2025, HBM Alpha Therapeutics (HBMAT), an innovative biotechnology company incubated by the Company, announced a strategic collaboration
More news about: Harbour BioMed
Aug 24, 2026, 05:35 ET European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
adrenal hyperplasia (CAH) to evaluate efficacy and safety.⁵-⁷With this designation, asedebart continues to build regulatory momentum across rare ACTH-driven disorders. Previous orphan designations include CAH in the European Union and the United States, and CAH and CD in Japan."Orphan
More news about: H. Lundbeck A/S
Aug 24, 2026, 05:33 ET European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
adrenal hyperplasia (CAH) to evaluate efficacy and safety.⁵-⁷With this designation, asedebart continues to build regulatory momentum across rare ACTH-driven disorders. Previous orphan designations include CAH in the European Union and the United States, and CAH and CD in Japan."Orphan
More news about: H. Lundbeck A/S
Aug 19, 2026, 02:03 ET Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
granted in Japan by the Ministry of Health, Labour and Welfare (MHLW) for asedebart for the treatment of patients with congenital adrenal hyperplasia (CAH) and Cushing's disease (CD).Conference callToday at 13.00 CET, Lundbeck will be hosting a conference call for the financial community.
More news about: H. Lundbeck A/S
Aug 19, 2026, 01:59 ET Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
granted in Japan by the Ministry of Health, Labour and Welfare (MHLW) for asedebart for the treatment of patients with congenital adrenal hyperplasia (CAH) and Cushing's disease (CD).Conference callToday at 13.00 CET, Lundbeck will be hosting a conference call for the financial community.
More news about: H. Lundbeck A/S
Aug 17, 2026, 06:30 ET Mosaic Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
61945CAH6 / US61945CAH60
More news about: The Mosaic Company
Aug 14, 2026, 16:15 ET Mosaic Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
Company61945CAH6 / US61945CAH60$400,000,000
More news about: The Mosaic Company
Aug 11, 2026, 06:45 ET Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance
guidanceDUBLIN, Ohio, Aug. 11, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2026 revenues of $63.7 billion, an increase of 6% from the fourth quarter of fiscal year 2025. Fourth quarter
More news about: Cardinal Health, Inc.
Aug 11, 2026, 06:40 ET Cardinal Health Board of Directors Approves Quarterly Dividend
DUBLIN, Ohio,, Aug. 11, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5158 per share, out of the Company's capital surplus. The dividend will
More news about: Cardinal Health
Aug 10, 2026, 08:25 ET Mosaic Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities
Company61945CAH6 / US61945CAH60$400,000,000
More news about: The Mosaic Company
Jul 20, 2026, 16:45 ET Cardinal Health expands home care business with two tuck-in acquisitions
DUBLIN, Ohio, July 20, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today it has entered into two definitive agreements that accelerate its at-Home Solutions' growth strategy.
More news about: Cardinal Health
Jul 14, 2026, 17:15 ET Cardiovascular Logistics Names Dr. Gary Kirsh Chief Executive Officer
States, comprising 1,000 providers across 250+ practice locations in 14 states. In November 2025, Solaris Health was acquired by Cardinal Health (NYSE: CAH) for approximately $2.4 billion, joining The Specialty Alliance and forming the cornerstone of its national Urology Alliance.A practicing urologist
More news about: Cardiovascular Logistics
Jul 10, 2026, 08:54 ET Runestone Partners With Raidiant To Power Gender-Inclusive 'Calling All Heroes' Overwatch Series
Under the agreement, Runestone will serve as an Official Partner of Raidiant and as Official Associate Partner for the upcoming Calling All Heroes (CAH) tournaments scheduled for August and September 2026. This collaboration marks Runestone's first entry into the Overwatch competitive
More news about: Raidiant
Jul 09, 2026, 06:45 ET Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11
DUBLIN, Ohio, July 9, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2026 on August 11, prior to the opening of trading on the New York Stock
More news about: Cardinal Health, Inc.
Jul 01, 2026, 16:05 ET Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH.
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 16:05 ET Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
classic CAH due to 11β-OHD. Although CRENESSITY is approved as an adjunctive treatment to GCs for patients with classic CAH regardless of enzyme deficiency, there is limited evidence on its use in this rare subtype. These findings support further exploration of CRENESSITY in this classic CAH subtype
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:35 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH); the value and benefits CRENESSITY brings to patients with CAH, including its potential to help address abnormal growth in pediatric patients with CAH by slowing bone age progression and improving predicted adult height in
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:30 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
(GC) treatment in adults with classic congenital adrenal hyperplasia (CAH) is associated with obesity, insulin resistance, increased cardiometabolic risk and adverse effects on bone health. In these analyses, adults with classic CAH taking CRENESSITY for up to two years experienced improvements in weight,
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 02:01 ET Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
levels.4Asedebart has received Orphan Drug Designation (ODD) for congenital adrenal hyperplasia (CAH) in the European Union and the United States as well as ODD in Japan for the treatment of patients with CD and CAH. About Cushing's diseaseCD is a rare endocrine disorder caused by a pituitary
More news about: H. Lundbeck A/S
Jun 15, 2026, 01:57 ET Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
levels.4Asedebart has received Orphan Drug Designation (ODD) for congenital adrenal hyperplasia (CAH) in the European Union and the United States as well as ODD in Japan for the treatment of patients with CD and CAH. About Cushing's diseaseCD is a rare endocrine disorder caused by a pituitary
More news about: H. Lundbeck A/S
Jun 10, 2026, 02:22 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
areas of significant unmet need.Asedebart has received Orphan Drug Designation (ODD) for CAH in the European Union and the United States as well as ODD in Japan for the treatment of patients with CD and CAH.Lu AG22515 data provide insight into CD40L pathway biologyAt ENDO, Lundbeck
More news about: H. Lundbeck A/S
Jun 10, 2026, 02:19 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
areas of significant unmet need.Asedebart has received Orphan Drug Designation (ODD) for CAH in the European Union and the United States as well as ODD in Japan for the treatment of patients with CD and CAH.Lu AG22515 data provide insight into CD40L pathway biologyAt ENDO, Lundbeck
More news about: H. Lundbeck A/S
Jun 03, 2026, 08:30 ET Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
life.In addition, Neurocrine will present a case series on the use of CRENESSITY in patients with classic CAH due to 11β‑hydroxylase deficiency, the second most common type of classic CAH after 21-hydroxylase deficiency, representing approximately 5% of all cases.Neurocrine will share the following
More news about: Neurocrine Biosciences, Inc.
May 18, 2026, 04:47 ET Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
patients with congenital adrenal hyperplasia (CAH) and Cushing's disease (CD). CAH and Cushing's disease are rare disorders with distinct origins and clinical features, but a shared underlying mechanism featuring elevated levels of ACTH.1,2 In CAH, impaired cortisol production leads to chronically
More news about: H. Lundbeck A/S
May 06, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
supraphysiologic glucocorticoid (GC) doses in patients with classic congenital adrenal hyperplasia (CAH) after starting CRENESSITYCRENESSITY reduces excess androgen production, enabling patients with classic CAH to move toward more physiologic GC dosing while maintaining essential daily cortisol replacement
More news about: Neurocrine Biosciences, Inc.